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Abstract 
Background: In human serum, a portion of homocysteine exists as an N-linked form to 
the ε-amino group of protein lysine residues. N-homocysteinylated proteins differ 
structurally and functionally from native proteins. The present study strives to develop 
detection and potential semi-quantification methods for N-homocysteinylated apoAI in 
human serum. 
Methods: Serum treated with or without cysteamine was supplied to isoelectric 
focusing followed by an immunoblot using an anti-apoAI antibody. Cysteamine 
treatment increased the isoelectric point for N-homocysteinylated apoAI, but not for 
unmodified apoAI, due to the presence of –SH group(s) derived from homocysteine and 
the absence of a cysteine residue in the apoAI molecule. N-homocysteinylated apoAI 
was semi-quantified from the scanned immunoblot pattern via a computer. 
Results: After cysteamine treatment, N-homocysteinylated apoAI in serum was 
identified by isoelectric focusing at the position with a higher pI value compared to 
intact apoAI. The reproducibility (between assays) of the semi-quantification method 
was 19.1% (CV) for an average ratio 5.9% of N-homocysteinylated apoAI to the whole 
apoAI in the serum. Approximately 1.0-7.4% of apoAI was N-homocysteinylated in 
serum obtained from 27 healthy subjects. Neither the ratio of N-homocysteinylated 
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apoAI nor its concentration, calculated by total apoAI concentration, indicated 
correlation with the so-called total (free and S-linked) homocysteine concentration. 
Conclusions: We directly found that a portion of apoAI in serum undergoes 
homocysteinylation in an N-linkage manner, and used this to develop a potential 
semi-quantification method for N-homocysteinylated apoAI.  
 
Introduction 
Hyperhomocysteinemia increases the risk of cardiovascular disease.1,2 Although the 
definite mechanism of homocysteine (Hcy) toxicity remains obscure, several 
mechanisms, including endothelial cell dysfunction,3,4 smooth muscle cell proliferation 
activation,5,6 thrombogenesis,7 and a reduced concentration of plasma high-density 
lipoproteins (HDL),8,9 have been reported to explain its role in the development of 
atherosclerosis. However, the effectiveness of lowering homocysteine levels by 
administering folate and vitamins B6 and B12 to reduce the risk of vascular events is 
controversial.10-12 
N-homocysteinylated protein (N-Hcy-protein), which is observed in human blood and 
cultured cells, may increase the potential risk of developing cardiovascular disease.13,14 
To prevent homocysteine from being used in protein biosynthesis, a portion of 
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homocysteine is converted to Hcy thiolactone (HcyT), a cyclic thioester, by 
methionyl-tRNA synthetase,15 HcyT reacts with proteins to form an amide bond with 
the ε-amino group in lysine residues, which leads to denaturation and/or dysfunction of 
the protein.13,15 These metabolic reactions occur in human endothelial cells at 
physiological conditions.16 N-Hcy-protein has been detected in human myocardium and 
aortic valve tissues as well as aortic lesions from apolipoprotein(apo)E-/- mice by 
immunohistochemical staining using a specific anti-N-Hcy-protein antibody.17 
Compared to the control, staining increased in mice fed a high-methionine diet. Undas 
and colleagues18 have indicated the existence of autoantibodies against N-Hcy-protein 
with ~32-fold variation in normal human plasma levels, which were positively 
correlated with the plasma total Hcy levels. Based on the contribution to the immune 
activation as a neo-self antigen, they hypothesize that autoantibodies against the 
N-Hcy-protein are important modulators of atherogenesis. 
 Recently, several methods have been developed to detect protein N-linked 
homocysteine.19-22 In one study, each of the purchased pure proteins was evaluated for 
N-linked homocysteine content, which varied over an extremely wide range from 
0.00006 mol Hcy/mol protein for chicken lysozyme to 0.470 mol Hcy/mol protein for 
human ferritin.19 In normal human plasma, about 3-7% of the total homocysteine 
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combines with proteins as N-linked homocysteine.19-21 Although it was reported that 
HDL and low-density lipoproteins (LDL) are also involved in N-homocysteinylation, 
data for their apolipoproteins such as apolipoprotein (apo) AI, apoAII, and apoB was 
not shown.22 
One of the mechanisms to protect against atherosclerosis by HDL and its major 
apolipoprotein, apoAI, is reverse cholesterol transport (RCT). In RCT excess 
cholesterol is extracted from atherosclerotic lesions, particularly macrophages 
accumulated by cholesteryl esters, and transported to the liver for excretion in the bile.23 
It is hypothesized that N-homocysteinylation of apoAI leads to RCT dysfunction and 
consequently, advanced atherosclerosis-prone lesions. 
Herein we develop a novel detection and semi-quantification method for 
N-homocysteinylated apoAI (N-Hcy-apoAI) to investigate the possibility of 
N-Hcy-apoAI as a potential independent biomarker for atherosclerotic diseases. 
 
Materials and methods 
Reagents 
L-homocysteine thiolactone hydrochloride, cysteamine hydrochloride, and Fat Red 7B, 
Atto 495 maleimide, and tris(2-carboxyethyl)phosphine hydrochloride were purchased 
 6
from Sigma Aldrich Japan (Tokyo, Japan). Pharmalyte 4-6.5, Sepharose CL-6B, and PD 
MidiTrap G-25 (3.5 mL) were purchased from GE Healthcare Bio-Sciences (Tokyo, 
Japan). ZOOM Strips pH 4-7, ZOOM Carrier Ampholytes pH 4-7 were purchased from 
Invitrogen Japan (Tokyo, Japan). Anti-human apolipoprotein AI polyclonal antibody 
(goat) was purchased from Academy Bio-Medical (Houston, TX, U.S.A.). Peroxidase 
(POD)-conjugated anti-goat IgG (rabbit) was purchased from Medical and Biological 
Laboratories (Nagoya, Japan). Unless otherwise stated, all other reagents were 
purchased from Wako Pure Chemical (Tokyo, Japan). 
 
Isolation of HDL 
HDL (1.063<d<1.21g/mL) was isolated from pooled human serum by 
ultracentrifugation as described previously,24 and dialyzed against 20 mM Tris-HCl (pH 
7.4) containing 1 mmol/L EDTA-2Na. HDL was applied to the Sepharose CL-6B 
column (1.5 x 97 cm), equilibrated with PBS to remove contaminated non-HDL 
lipoproteins, and the purified HDL fraction was concentrated by ultrafiltration. 
 
N-homocysteinylation of apoAI 
N-homocysteinylation reactions were carried out as described previously.25 Briefly, 100 
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µL of HDL suspension (approx. 10 mg protein/mL) was mixed with 25 µL of 6 mmol/L 
HcyT hydrochloride (dissolved in 20 mmol/L Tris-HCl (pH 10.4) to reach a neutral pH 
solution), 1.5 µL of 2% NaN3, and 23.5 µL of 20 mmol/L Tris-HCl (pH7.4), followed by 
incubation overnight at 4°C. The control HDL sample was prepared in a similar manner 
except the HcyT solution was replaced with saline. 
  
Detection of sulfhydryl groups (-SH) 
HcyT-treated HDL (approx. 6.7 mg protein/mL) was mixed with the control HDL 
(approx. 6.7 mg protein/mL) at different rates (10:0, 8:2, 4:6, 3:7, 2:8, 0:10), so that the 
mixtures were maintained at the same composition of apolipoproteins and lipids. The 
mixtures, diluted twice by 20 mmol/L Tris-HCl (pH7.4), were added to equal volumes 
of 14 mmol/L Tris(2-carboxyethyl)phosphine hydrochloride (Sigma), incubated for 1 h, 
and then incubated with fluorescent-conjugated maleimide (Atto 495 maleimide) for 2 h 
to label the sulfhydryl groups (–SH) of the apolipoproteins. The HDL fractions were 
separated from the free fluorescent-conjugated maleimide by PD MidiTrap G-25. The 
HDL fractions (100 µL) were placed into the wells of an ELISA plate and the 
fluorescent intensities were measured by Corona Multi Microplate Reader MTP-800 
(Hitachi High-Technologies, Tokyo, Japan) at excitation and emission wavelengths of 
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492 and 530 nm, respectively. 
 
Detection of N-Hcy apoAI 
Serum and HcyT-treated HDL were mixed with a cysteamine hydrochloride solution 
(dissolved in 20 mmol/L Tris-HCl (pH 10.4) to realize a neutral pH) to give a final 
protein concentration of approximately 21 µg/µL and 4 µg/µL, respectively, which 
contained a 6.7-fold amount of cysteamine against protein. This mixture was incubated 
overnight at 37°C . The cysteamine-treated samples were delipidated with 
chloroform/methanol/ether (4:2:1, v/v) and washed with ether. The pellets were 
resuspended in 8 mol/L urea, and approximately 75 µg and 7.5 µg protein for serum and 
HcyT-treated HDL, respectively, were applied to isoelectric focusing (IEF) with a pH 
range from 4.0 to 6.5. Separated proteins were electrophoretically transferred onto a 
PVDF membrane (Immobilon-P, Millipore, Billerica, MA, USA), incubated with 20 
mmol/L TBS (pH 7.6) containing 5% skim milk and 0.05% Tween 20 (blocking buffer) 
for 1 h at room temperature, and subsequently washed with TBS containing 0.05% 
Tween 20 (washing buffer). The membrane was then incubated with anti-apoAI 
antibody (goat) in TBS containing 0.5% skim milk for 1 h. After washing thrice with the 
washing buffer, the membrane was incubated with POD-conjugated anti-goat IgG for 1 
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h. Finally, the membrane was carefully washed, and the bands containing apoAI were 
visualized using 3,3’-diaminobenzidine tetrahydrochloride and hydrogen peroxide. As 
shown in Figure 1, apoAI usually does not react with cysteamine due to the absence of a 
cysteine residue in its molecules. In contrast, N-Hcy-apoAI has a free –SH group 
derived from Hcy in the apoAI molecule; hence, it does react with cysteamine. Thus, 
cysteamine treatment influences the isoelectric point (pI) of N-Hcy-apoAI, which 
changes toward the basic direction, but not unmodified apoAI. 
 
Analysis of HcyT-treated HDL particles 
The profiles of HcyT-treated HDL were analyzed by agarose-gel electrophoresis using a 
commercial kit (Rep-Lip, Helena Laboratories, USA). Briefly, 1 µL of 
N-homocysteinylated HDL (approx. 10 µg protein) was added to the sample wells in a 
1% agarose film. After electrophoresis, separated HDL was directly stained with Fat 
Red 7B. To assess HDL particle size, electrophoresis was carried out using 4-12% 
non-denaturing gradient gel (Invitrogen Japan, Tokyo, Japan) directly stained with CBB 
R-250. 
 
Two-dimensional Electrophoresis (2DE) 
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2DE was performed using ZOOM IPGRunner (Invitrogen). HcyT-treated HDL (1 µL) 
was mixed with 1 µL of ZOOM Carrier Ampholytes 4-7 (Invitrogen), 146 µL of the 
sample diluent (8 mol/L urea, 2% CHAPS, 0.002% bromophenol blue), 6 µL of D.W., 
and the mixture was applied to a ZOOM Strip (pH4-7; Invitrogen). After allowing the 
strip to swell (for at least 1 h), the proteins were focused using the protocol described in 
the instructions, and the strip was immediately applied to second dimensional 
SDS-PAGE. Finally, the gel was stained with CBB R-250. 
 
Semi-quantification of N-Hcy apoAI 
Blood samples were drawn from apparently healthy volunteers (n=27) who gave 
informed consent. The study was approved by our institutional research ethics 
committee. A pair of serum samples, with and without cysteamine treatment, was 
determined by IEF followed by immunoblot for apoAI. The bands of the apoAI 
isoforms were digitally scanned using a Cannon MP610 and analyzed with a CS 
Analyzer (ATTO, Japan). To calculate the ratio of N-Hcy-apoAI to total apoAI, we 
defined N-Hcy-apoAI as the band observed at the position that is one charge basic 
compared to intact apoAI. Actually, the ratio of N-Hcy-apoAI was calculated by 
subtracting the ratio obtained without cysteamine treatment from that with cysteamine 
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treatment, since a nonspecific band was occasionally observed at that position without 
cysteamine treatment. 
 
Results 
Detection of N-homocysteinylated apoAI in normal human serum 
The profile of apoAI isoforms in normal human serum was analyzed by isoelectric 
focusing and a subsequent immunoblot using the anti-apoAI antibody. Cysteamine 
treatment of the serum resulted in an increase or the appearance of more basic apoAI 
isoforms compared to the intact apoAI band (Figure 2). The change in the pI values of 
the apoAI isoforms observed in the serum treated with cysteamine was equivalent to 1 
and 2 charges toward the basic direction, indicating that part of the apoAI may include 
–SH group(s) in the molecules. 
 
Synthesis of N-Hcy-apoAI by HcyT treatment of HDL 
Prior to cysteamine treatment, HDL was incubated with or without HcyT, and the 
profile of the apoAI isoforms was analyzed by isoelectric focusing and a subsequent 
immunoblot using the anti-apoAI antibody. Incubated HDLs without HcyT had similar 
patterns as those of normal sera both treated and untreated with cysteamine, but the 
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pre-incubation with HcyT followed by cysteamine treatment induced at least five new 
apoAI isoforms toward the basic direction, reflecting plural N-linked Hcy in one apoAI 
molecule (Figure 3). The minimum concentration of HcyT for the statistically 
significant increase of N-Hcy-apoAI in vitro was estimated at 0.25 mmol/L using the 
present N-homocysteinylation and detected methods, however, the trend of the 
occurrence of N-homocysteinylation was observed at 0.05-0.10 mmol/L of HcyT on the 
immunoblot patterns (data not shown). 
To confirm that the new apoAI isoforms were formed by N-linked homocysteinylation, 
the isoforms were subsequently visualized by cysteamine treatment; HDL treated with 
HcyT was mixed with untreated HDL at different ratio (10:0, 8:2, 4:6, 3:7, 2:8, 0:10). 
Consequently, each mixture intrinsically included the same number of original cysteine 
residues. The –SH groups in the mixtures were then labeled by fluorescent-labeled 
maleimide, and detected at excitation and emission wavelengths of 492 and 530 nm, 
respectively. The fluorescent intensity increased in proportion with the concentration of 
HDL treated with HcyT, indicating the existence of newly generated –SH groups due to 
N-linked homocysteinylation by HcyT treatment, but N-linked homocysteinylation may 
have occurred in all of the apolipoproteins, including apoAI in HDL (Figure 4). 
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Characterization of HcyT-treated HDL 
Although the particle sizes of HcyT-treated HDL and intact HDL on a native-PAGE 
were similar (Figure 5A), HcyT-treated HDL moved slightly faster to the anode side on 
agarose gel electrophoresis (Figure 5B). To confirm that the raised pI values of apoAI in 
HDL sequentially treated with HcyT and cysteamine were not due to fragmentation 
caused by the treatments, 2DE was carried out (Figure 5C). ApoAI isoforms with a 
higher pI value than intact apoAI, which can be regarded as N-Hcy-apoAIs, indicated 
that N-Hcy-apoAIs and intact apoAI have almost the same molecular weight, 
suggesting the raised pI values by both treatments are not due to fragmentation of 
apoAI. 
 
Concentration of N-Hcy apoAI in healthy subjects 
The N-Hcy-apoAI concentration was calculated by multiplying its ratio (obtained as 
described in the “Materials and methods”) with the total apoAI concentration in serum 
obtained by a turbidimetric immunoassay. The reproducibility of the semi-quantification 
method, obtained by three independent determinations performed in triplicate, was 
19.1% (CV) for an average ratio 5.9% of N-homocysteinylated apoAI to the whole 
apoAI in the normal serum. Although the ratios of N-Hcy-apoAI to the total apoAI 
 14
varied from 1.0% to 7.4% (from concentrations of 1.2 to 14.5 mg/dL) in 27 healthy 
subjects, a relatively high correlation (r=0.673) between N-Hcy-apoAI and the total 
serum apoAI concentration was observed (Figure 6A). 
Additionally, neither the quantity (Figure 6B) nor the ratio against total apoAI (Figure 
6C) of N-Hcy-apoAI was correlated with total homocysteine concentration, which 
included all of free Hcy, Hcy homodimer, Hcy-cysteine heterodimer, and Hcy S-linked 
to plasma proteins, but not Hcy N-linked to plasma proteins (r=-0.088 and r=-0.151, 
respectively). 
 
Discussion 
Because the apoAI molecule lacks a cysteine residue, it does not react with cysteamine, 
which easily combines with protein through the –SH groups to increase the protein pI 
value. Therefore, if apoAI profiles on IEF are affected by cysteamine treatment, it is 
speculated that apoAI acquires –SH group(s) according to N-homocysteinylation. In 
fact, some of the apoAI isoforms in the IEF patterns were observed at positions of 
higher pI values after cysteamine treatment of normal serum and HDL. 
N-homocysteinylation of HDL with HcyT followed by cysteamine treatment increased 
the amount of newly developed apoAI isoforms with more basic pI values as well as the 
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large extent of change in the pI values on IEF. These data indicate that a portion of the 
apoAI molecules include –SH group(s) derived from Hcy, and that this method can 
determine N-Hcy-apoAI. To confirm the existence of –SH group(s), HDL treated with 
HcyT was labeled with fluorescent-conjugated maleimide, which specifically binds to 
–SH groups. The increased fluorescent intensity relative to the increased ratio of 
HcyT-treated HDL in the mixtures with untreated HDL indicates that –SH groups 
increase in apolipoproteins, including apoAI in HDL treated with HcyT, although the 
basic intensity for the sample consisting of 100% untreated HDL is derived from the 
–SH groups in the original cysteine residues. 
Under physiological conditions, one or two lysine residue(s) of the 21 lysine residues in 
the apoAI molecule are involved in N-homocysteinylation (Figure 2). In vitro, protein 
N-homocysteinylation occurs even at HcyT concentrations as low as 10 nmol/L,25 
which is similar to physiological conditions (between 0 and 35 nmol/L).26 In contrast, 
HDL incubated with an extremely high concentration of HcyT, which is approximately 
a 100,000-fold of human plasma (1mmol/L), yields an extensive homocysteinylation in 
which a maximum of 5 or 6 lysine residues in apoAI molecle are likely modified by 
Hcy (Figure 3). To understand the effect of apoAI N-homocysteinylation on its 
physiological functions, further analysis to identify the N-homocysteinylated site(s) 
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should be important. 
Agarose gel electrophoresis (Figure 5B) demonstrated a slightly increased negative 
charge for HDL treated by HcyT, suggesting that N-homocysteinylation causes an 
apoAI conformation change in the HDL particle and/or that the ε-amino group(s) of the 
lysine residue(s) possesses a higher pI value than α-amino group(s) of homocysteine 
residue(s). However, significant changes in the HDL particle size were not observed 
after HcyT treatment by a native PAGE (Figure 5A). To exclude the possibility that the 
change in the pI values of apoAI treated with a high concentration of HcyT is due to 
fragmentation of apoAI, 2DE, IEF for first dimension and subsequent by SDS-PAGE 
for second dimension, were performed. Although the apparent molecular weight did not 
differ from that of intact apoAI, approximately 28 kDa, N-Hcy-apoAI was observed at 
positions where the pI values were higher than the intact apoAI as described above 
(Figure 5C). Treatments by HcyT and cysteamine did not cause fragmentation of apoAI. 
The N-Hcy-apoAI concentration, which was calculated from the total apoAI 
concentration, shows a relatively high correlation (r=0.673) with total apoAI 
concentration as a group (Figure 6A). However, the possibility of N-Hcy-apoAI as an 
independent biomarker for an individual progressive atherosclerosis is undeniable since 
the N-Hcy-apoAI values widely varied (from 1.8 to 11.9 mg/dL) among the individuals 
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whose total apoAI levels in serum were similar (around 150 mg/dL). In contrast, 
consistent with the previous report by Jakubowski and coworkers,27 N-Hcy-apoAI and 
the total homocysteine concentration were not correlated (Figure 6B, 6C). 
The N-homocysteinylation levels vary among the types of proteins in plasma. For 
example, no N-homocysteinylated transthyretin was found in plasma obtained from 
patients with hyperhomocysteinemia,28 and 50% of ferritin have been undergone 
N-homocysteinylation in commercially available purified proteins.19 Therefore, the 
maximum N-homocysteinylation ratio in the present study of 7.4% for apoAI is 
conceivable. Although some methods for total N-Hcy-proteins assay are available, few 
reports on individual plasma proteins have been published. Thus, to analyze the 
progression of atherosclerosis-prone legions, determination of N-Hcy-apoAI should 
provide more beneficial information than that of N-Hcy-proteins. 
However, the method herein has limitations as a rigorous quantification assay. First, 
proapoAI and deamidated apoAI as well as intact apoAI exist in plasma as the isoforms 
of apoAI.29, 30 In isoelectric focusing after treatment with cysteamine, N-Hcy-apoAI at 
one lysine residue would show a similar isoelectric point with singly deamidated apoAI, 
which is simultaneously appended by two molecules of N-linked homocysteines. Hence, 
the apparently intact apoAI band after treatment with cysteamine may include not only 
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singly deamidated apoAI modified by one molecule of N-linked homocysteine but also 
doubly deamidated apoAI modified by two molecules of N-linked homocysteines. 
However, maintaining a neutral pH during the incubation with cysteamine would avoid 
deamidation and cause the aforementioned isoforms, including N-homocysteinylation 
and deamidation, to be negligible. In the present study, the ratio of N-Hcy-apoAI is 
defined as the ratio of the apoAI isoform with an increased isoelectric point equivalent 
to one charge compared to intact apoAI when the serum is treated with cysteamine. 
Second, it is unclear whether N-Hcy-apoAI has the same reactivity with the antibody as 
intact apoAI. Actually, modified apoAIs, such as nitration and chlorination of tyrosine 
residues, often induce higher reactivity than intact apoAI on immunoblot assays.31 
Despite of these limitations, the current method could be useful to elucidate whether 
N-Hcy-apoAI leads to advanced atherosclerosis-prone lesions. 
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FIGURE LEGENDS 
Figure 1 Schematic representation of intact apoAI (top), N-Hcy-apoAI (middle), and 
cysteamine treated N-Hcy-apoAI (bottom). N-Hcy-apoAI, but not intact apoAI, reacts 
with cysteamine due to the presence of the –SH group derived from homocysteine. 
 
Figure 2 Detection of N-homocysteinylated apoAI in normal human serum. Sera 
obtained from two individuals (a and b) with (+) and without (-) cysteamine treatment 
were analyzed by IEF followed by an immunoblot using an anti-apoAI antibody for the 
apoAI isoforms. The concentration of total apoAI and the ratio of N-Hcy-apoAI for 
serum a and b were also indicated. 
 
Figure 3 Synthesis of N-Hcy-apoAI by HcyT treatment of HDL. HDL suspension 
(approx. 1 mg protein) was treated with 1 mmol/L HcyT hydrochloride (HcyT +). 
Control HDL sample was prepared in a similar manner except saline was used instead 
of HcyT solution (HcyT -). Both HDLs were treated with (+) or without (-) cysteamine 
followed by IEF. ApoAI isoforms were visualized by an immunoblot using anti-apoAI 
antibody. 
 
 24
Figure 4 Detection of newly generated –SH groups due to N-linked homocysteinylation 
by HcyT treatment. HDL treated with HcyT was mixed with untreated HDL at different 
ratios, and the –SH groups in the mixtures were labeled by fluorescent-labeled 
maleimide. Fluorescent intensities of the HDL fractions, which were separated from the 
free fluorescent-conjugated maleimide by PD MidiTrap G-25, were measured. 
 
Figure 5 Characterization of HcyT-treated HDL particles. Panels A and B, control HDL 
(a; untreated) and HDL incubated without (b) or with (c) HcyT were analyzed by 
comparing size and charge using non-denaturing PAGE followed by CBB R-250 
staining (A) and agarose-gel electrophoresis followed by Fat Red 7B staining (B). Panel 
C depicts the effect of HcyT treatment on the molecular size of apoAI in HDL particles, 
2DE was performed and the gel was stained with CBB R-250. (*) and (#) indicate the 
isoforms of intact apoAI and N-Hcy-apoAIs, respectively. 
 
Figure 6 Correlation between N-Hcy-apoAI and total apoAI (A), and total Hcy (B), and 
between N-Hcy-apoAI/apoAI ratio in serum and total Hcy (C) in plasma. The Spearman 
correlation coefficient (r) and statistical significance (P) are shown. 
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